JAGX
Jaguar Health, Inc.
Price Chart
Latest Quote
$2.73
+0.05 (+1.87%)
Current Price
| Previous Close | $2.68 |
| Open | $2.66 |
| Day High | $2.83 |
| Day Low | $2.66 |
| Volume | 31,776 |
Stock Information
| Shares Outstanding | 832K |
| Total Debt | $34.31M |
| Cash Equivalents | $7.28M |
| Revenue | $29.57M |
| Net Income | $-50.13M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.27M |
| EPS (TTM) | $-695.50 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $36.58M |
| Sales | $29.57M |
| Income | $-50.13M |
| Book/sh | $-38.12 |
| Cash/sh | $8.74 |
| Employees | 47 |
Financial Ratios
| Quick Ratio | 0.24 |
| Current Ratio | 0.65 |
Returns & Margins
| ROA | -35.86% |
| Gross Margin | 85.06% |
| Operating Margin | 50.23% |
| Profit Margin | -115.40% |
Ownership
| Insider Ownership | 4.95% |
| Institutional Ownership | 0.94% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.48 |
| P/S | 0.08 |
| P/B | -0.07 |
Analyst Data
| Recommendation | none |
| Target Price | $262.50 |
Technical Indicators
| SMA20 | $2.79 |
| SMA50 | $5.31 |
| SMA200 | $32.91 |
| RSI | 41.26 |
| ATR | 0.2919 |
| Shares Float | 577K |
| Short Float | 9.29% |
| Short Ratio | 0.42 |
| Volatility | -0.10 |
| Rel Volume | 0.34 |
Performance History
| Week | +14.71% |
| Month | -12.22% |
| Quarter | -81.25% |
| 6 Months | -93.45% |
| YTD | -92.18% |
| Year | -97.44% |
| 3 Years | -99.99% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $2.73 | 31,776 |
| 2026-06-24 | $2.68 | 94,400 |
| 2026-06-23 | $2.56 | 103,100 |
| 2026-06-22 | $2.61 | 280,400 |
| 2026-06-18 | $2.25 | 216,500 |
| 2026-06-17 | $2.38 | 331,400 |
| 2026-06-16 | $2.31 | 36,100 |
| 2026-06-15 | $2.47 | 63,000 |
| 2026-06-12 | $2.69 | 56,700 |
| 2026-06-11 | $2.82 | 44,300 |
| 2026-06-10 | $2.75 | 26,700 |
| 2026-06-09 | $2.82 | 26,100 |
| 2026-06-08 | $2.73 | 79,600 |
| 2026-06-05 | $2.80 | 135,900 |
| 2026-06-04 | $3.05 | 46,000 |
| 2026-06-03 | $2.92 | 47,200 |
| 2026-06-02 | $3.22 | 21,100 |
| 2026-06-01 | $3.27 | 51,400 |
| 2026-05-29 | $3.55 | 69,200 |
| 2026-05-28 | $3.29 | 96,000 |
| 2026-05-27 | $3.19 | 58,600 |
| 2026-05-26 | $3.11 | 99,600 |
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
đ° Latest News
Sector Update: Healthcare Stocks Rise Late Afternoon
MT Newswires âĸ 2026-06-22T19:43:27ZJaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
GuruFocus.com âĸ 2026-05-26T21:00:17ZJaguar Health (JAGX) Q3 2025 Earnings Transcript
Motley Fool âĸ 2026-05-21T21:10:08Z
Jaguar (JAGX) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-05-20T16:41:09Z
Jaguar Health Inc (JAGX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
GuruFocus.com âĸ 2026-04-11T07:00:34ZBC-Most Active Stocks
Associated Press Finance âĸ 2026-01-16T15:30:28ZSector Update: Health Care Stocks Softer Late Afternoon
MT Newswires âĸ 2025-11-20T20:53:30ZJaguar Health Inc (JAGX) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Ongoing Challenges
GuruFocus.com âĸ 2025-11-17T21:00:46Z
Jaguar Health Completes Private Placement Deal
Insider Monkey âĸ 2025-09-21T13:10:40Z
Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs
TipRanks âĸ 2025-06-26T13:15:50Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,430,000 | $1,437,000 | $2,037,000 | $2,019,000 |
| Cost Of Revenue | $3,774,000 | $1,955,000 | $2,037,000 | $2,019,000 |
| Total Revenue | $11,511,000 | $11,689,000 | $9,761,000 | $11,956,000 |
| Operating Revenue | $15,497,000 | $15,584,000 | $13,607,000 | $15,019,000 |
| Expenses | ||||
| Interest Expense | $67,000 | $231,000 | $6,382,000 | $12,723,000 |
| Total Expenses | $56,619,000 | $42,520,000 | $43,681,000 | $46,371,000 |
| Rent Expense Supplemental | $511,000 | $817,000 | $877,000 | $629,000 |
| Other Income Expense | $-8,822,000 | $-8,189,000 | $-1,599,000 | $-1,257,000 |
| Other Non Operating Income Expenses | $43,000 | $51,000 | $200,000 | $950,000 |
| Net Non Operating Interest Income Expense | $-67,000 | $-231,000 | $-6,382,000 | $-12,723,000 |
| Interest Expense Non Operating | $67,000 | $231,000 | $6,382,000 | $12,723,000 |
| Operating Expense | $52,845,000 | $40,565,000 | $41,644,000 | $44,352,000 |
| Selling And Marketing Expense | $4,169,000 | $4,094,000 | $3,283,000 | $5,155,000 |
| General And Administrative Expense | $21,852,000 | $18,089,000 | $19,765,000 | $21,550,000 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-53,434,000 | $-38,492,000 | $-41,300,000 | $-47,454,000 |
| Net Interest Income | $-67,000 | $-231,000 | $-6,382,000 | $-12,723,000 |
| Normalized Income | $-44,569,000 | $-30,252,000 | $-39,501,000 | $-45,247,000 |
| Net Income From Continuing And Discontinued Operation | $-53,434,000 | $-38,492,000 | $-41,300,000 | $-47,454,000 |
| Total Operating Income As Reported | $-45,908,000 | $-30,831,000 | $-34,291,000 | $-34,415,000 |
| Net Income Common Stockholders | $-53,575,000 | $-38,492,000 | $-41,300,000 | $-47,454,000 |
| Net Income | $-53,434,000 | $-38,492,000 | $-41,300,000 | $-47,454,000 |
| Net Income Including Noncontrolling Interests | $-53,997,000 | $-39,251,000 | $-41,901,000 | $-48,395,000 |
| Net Income Continuous Operations | $-53,997,000 | $-39,251,000 | $-41,901,000 | $-48,395,000 |
| Pretax Income | $-53,997,000 | $-39,251,000 | $-41,901,000 | $-48,395,000 |
| Special Income Charges | $-2,599,000 | $1,245,000 | $3,326,000 | $-2,187,000 |
| Operating Income | $-45,108,000 | $-30,831,000 | $-33,920,000 | $-34,415,000 |
| Depreciation Amortization Depletion Income Statement | $1,858,000 | $1,840,000 | - | - |
| Depreciation And Amortization In Income Statement | $1,858,000 | $1,840,000 | - | - |
| Gross Profit | $7,737,000 | $9,734,000 | $7,724,000 | $9,937,000 |
| Per Share | ||||
| Diluted EPS | $-803.95 | $-4574.15 | $-29542.20 | $-1129857.14 |
| Basic EPS | $-803.95 | $-4574.15 | $-29542.20 | $-1129857.14 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-42,863,000 | $-28,422,000 | $-31,332,000 | $-31,173,000 |
| Total Unusual Items | $-8,865,000 | $-8,240,000 | $-1,799,000 | $-2,207,000 |
| Total Unusual Items Excluding Goodwill | $-8,865,000 | $-8,240,000 | $-1,799,000 | $-2,207,000 |
| Reconciled Depreciation | $2,202,000 | $2,358,000 | $2,388,000 | $2,292,000 |
| EBITDA (Bullshit earnings) | $-51,728,000 | $-36,662,000 | $-33,131,000 | $-33,380,000 |
| EBIT | $-53,930,000 | $-39,020,000 | $-35,519,000 | $-35,672,000 |
| Diluted Average Shares | $66,640 | $8,415 | $1,398 | $42 |
| Basic Average Shares | $66,640 | $8,415 | $1,398 | $42 |
| Diluted NI Availto Com Stockholders | $-53,575,000 | $-38,492,000 | $-41,300,000 | $-47,454,000 |
| Preferred Stock Dividends | $141,000 | - | - | - |
| Minority Interests | $563,000 | $759,000 | $601,000 | $941,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $1,799,000 | $-1,245,000 | $-3,697,000 | $2,187,000 |
| Impairment Of Capital Assets | $800,000 | $0 | $371,000 | $0 |
| Gain On Sale Of Security | $-6,266,000 | $-9,485,000 | $-5,125,000 | $-20,000 |
| Research And Development | $24,966,000 | $16,542,000 | $18,596,000 | $17,647,000 |
| Selling General And Administration | $26,021,000 | $22,183,000 | $23,048,000 | $26,705,000 |
| Other Gand A | $11,480,000 | $8,169,000 | $9,660,000 | $9,869,000 |
| Rent And Landing Fees | $511,000 | $817,000 | $877,000 | $629,000 |
| Salaries And Wages | $9,861,000 | $9,103,000 | $9,228,000 | $11,052,000 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-33,310,000 | $-11,194,000 | $-15,155,000 | $-23,096,000 |
| Total Assets | $38,323,000 | $53,425,000 | $50,763,000 | $47,452,000 |
| Total Non Current Assets | $17,978,000 | $21,227,000 | $22,800,000 | $25,131,000 |
| Other Non Current Assets | $494,000 | $1,348,000 | $1,012,000 | $995,000 |
| Goodwill And Other Intangible Assets | $16,021,000 | $18,479,000 | $20,116,000 | $22,439,000 |
| Other Intangible Assets | $16,021,000 | $18,479,000 | $20,116,000 | $22,439,000 |
| Current Assets | $20,345,000 | $32,198,000 | $27,963,000 | $22,321,000 |
| Other Current Assets | $2,216,000 | $12,204,000 | $10,121,000 | $7,361,000 |
| Restricted Cash | $6,864,000 | $0 | - | - |
| Inventory | $8,599,000 | $10,345,000 | $9,189,000 | $7,024,000 |
| Receivables | $1,698,000 | $1,647,000 | $2,184,000 | $2,467,000 |
| Other Receivables | $177,000 | $120,000 | $217,000 | $588,000 |
| Accounts Receivable | $1,521,000 | $1,527,000 | $1,967,000 | $1,879,000 |
| Cash Cash Equivalents And Short Term Investments | $968,000 | $8,002,000 | $6,469,000 | $5,469,000 |
| Cash And Cash Equivalents | $968,000 | $8,002,000 | $6,469,000 | $5,469,000 |
| Cash Financial | $968,000 | $8,002,000 | $6,469,000 | $5,469,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $41,555,000 | $27,539,000 | $29,391,000 | $28,158,000 |
| Total Debt | $43,607,000 | $36,526,000 | $37,094,000 | $34,835,000 |
| Long Term Debt And Capital Lease Obligation | $15,975,000 | $24,189,000 | $31,879,000 | $18,469,000 |
| Long Term Debt | $15,083,000 | $23,503,000 | $30,993,000 | $17,744,000 |
| Current Debt And Capital Lease Obligation | $27,632,000 | $12,337,000 | $5,215,000 | $16,366,000 |
| Current Debt | $27,440,000 | $12,038,000 | $4,867,000 | $15,883,000 |
| Other Current Borrowings | $27,440,000 | $12,038,000 | $4,867,000 | $15,883,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $57,011,000 | $46,931,000 | $45,866,000 | $48,808,000 |
| Total Non Current Liabilities Net Minority Interest | $16,357,000 | $27,227,000 | $31,879,000 | $18,469,000 |
| Non Current Deferred Liabilities | $382,000 | $553,000 | $0 | - |
| Current Liabilities | $40,654,000 | $19,704,000 | $13,987,000 | $30,339,000 |
| Current Deferred Liabilities | $170,000 | $170,000 | $0 | - |
| Payables And Accrued Expenses | $12,852,000 | $7,197,000 | $8,772,000 | $13,973,000 |
| Interest Payable | $5,000 | $4,000 | $719,000 | $5,489,000 |
| Payables | $8,785,000 | $5,400,000 | $5,266,000 | $6,393,000 |
| Total Tax Payable | $99,000 | $114,000 | $292,000 | $585,000 |
| Accounts Payable | $8,686,000 | $5,286,000 | $4,974,000 | $5,808,000 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-19,774,000 | $7,285,000 | $4,961,000 | $-657,000 |
| Preferred Stock Equity | $2,485,000 | - | - | - |
| Total Equity Gross Minority Interest | $-18,688,000 | $6,494,000 | $4,897,000 | $-1,356,000 |
| Stockholders Equity | $-17,289,000 | $7,285,000 | $4,961,000 | $-657,000 |
| Gains Losses Not Affecting Retained Earnings | $-833,000 | $-467,000 | $-652,000 | $-680,000 |
| Other Equity Adjustments | $-833,000 | $-467,000 | $-652,000 | $-680,000 |
| Retained Earnings | $-399,916,000 | $-346,482,000 | $-308,249,000 | $-266,948,000 |
| Preferred Securities Outside Stock Equity | - | $2,485,000 | $0 | - |
| Other | ||||
| Ordinary Shares Number | $199,329 | $15,098 | $1,398 | $42 |
| Share Issued | $199,329 | $15,098 | $1,398 | $42 |
| Tangible Book Value | $-35,795,000 | $-11,194,000 | $-15,155,000 | $-23,096,000 |
| Invested Capital | $22,749,000 | $42,826,000 | $40,821,000 | $32,970,000 |
| Working Capital | $-20,309,000 | $12,494,000 | $13,976,000 | $-8,018,000 |
| Capital Lease Obligations | $1,084,000 | $985,000 | $1,234,000 | $1,208,000 |
| Total Capitalization | $-2,206,000 | $30,788,000 | $35,954,000 | $17,087,000 |
| Minority Interest | $-1,399,000 | $-791,000 | $-64,000 | $-699,000 |
| Additional Paid In Capital | $380,974,000 | $354,234,000 | $313,862,000 | $266,971,000 |
| Capital Stock | $2,486,000 | $0 | $0 | $0 |
| Common Stock | $1,000 | $0 | $0 | $0 |
| Preferred Stock | $2,485,000 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $382,000 | $553,000 | $0 | - |
| Long Term Capital Lease Obligation | $892,000 | $686,000 | $886,000 | $725,000 |
| Current Deferred Revenue | $170,000 | $170,000 | $0 | - |
| Current Capital Lease Obligation | $192,000 | $299,000 | $348,000 | $483,000 |
| Current Accrued Expenses | $4,067,000 | $1,797,000 | $3,506,000 | $7,580,000 |
| Net PPE | $1,463,000 | $1,400,000 | $1,672,000 | $1,697,000 |
| Accumulated Depreciation | $-558,000 | $-513,000 | $-465,000 | $-404,000 |
| Gross PPE | $2,021,000 | $1,913,000 | $2,137,000 | $2,101,000 |
| Other Properties | $477,000 | $477,000 | $477,000 | $1,617,000 |
| Machinery Furniture Equipment | $194,000 | $221,000 | $282,000 | $88,000 |
| Buildings And Improvements | $954,000 | $819,000 | $982,000 | - |
| Land And Improvements | $396,000 | $396,000 | $396,000 | $396,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-2,000,000 | $0 | - | - |
| Finished Goods | $1,322,000 | $1,088,000 | $615,000 | $1,324,000 |
| Work In Process | $7,236,000 | $7,407,000 | $6,517,000 | $3,599,000 |
| Raw Materials | $2,041,000 | $1,850,000 | $2,057,000 | $2,101,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-23,727,000 | $-29,615,000 | $-33,242,000 | $-34,779,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-23,686,000 | $-29,384,000 | $-33,242,000 | $-33,104,000 |
| Cash Flow From Continuing Operating Activities | $-23,686,000 | $-29,384,000 | $-33,242,000 | $-33,104,000 |
| Operating Gains Losses | $1,961,000 | $-1,107,000 | $-3,646,000 | $2,187,000 |
| Investing Activities | ||||
| Capital Expenditure | $-41,000 | $-231,000 | - | $-1,675,000 |
| Investing Cash Flow | $-41,000 | $-231,000 | $0 | $-1,675,000 |
| Cash Flow From Continuing Investing Activities | $-41,000 | $-231,000 | $0 | $-1,675,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,977,000 | $31,910,000 | $32,711,000 | $20,462,000 |
| Financing Cash Flow | $23,670,000 | $31,202,000 | $34,227,000 | $23,181,000 |
| Cash Flow From Continuing Financing Activities | $23,670,000 | $31,202,000 | $34,227,000 | $23,181,000 |
| Net Other Financing Charges | $-652,000 | $-608,000 | $1,233,000 | $-1,156,000 |
| Net Preferred Stock Issuance | $2,377,000 | $0 | $611,000 | $0 |
| Preferred Stock Issuance | $2,377,000 | $0 | $611,000 | $0 |
| Net Common Stock Issuance | $8,600,000 | $31,910,000 | $32,100,000 | $20,462,000 |
| Common Stock Issuance | $8,600,000 | $31,910,000 | $32,100,000 | $20,462,000 |
| Other | ||||
| Repayment Of Debt | $-752,000 | $-708,000 | $-953,000 | $-1,256,000 |
| Issuance Of Debt | $13,445,000 | $0 | $0 | $3,975,000 |
| Interest Paid Supplemental Data | $22,000 | $14,000 | $35,000 | $23,000 |
| End Cash Position | $7,832,000 | $8,002,000 | $6,469,000 | $5,469,000 |
| Beginning Cash Position | $8,002,000 | $6,469,000 | $5,469,000 | $17,051,000 |
| Effect Of Exchange Rate Changes | $-113,000 | $-54,000 | $15,000 | $16,000 |
| Changes In Cash | $-57,000 | $1,587,000 | $985,000 | $-11,598,000 |
| Net Issuance Payments Of Debt | $12,693,000 | $-708,000 | $-953,000 | $2,719,000 |
| Net Long Term Debt Issuance | $12,693,000 | $-708,000 | $-953,000 | $2,719,000 |
| Long Term Debt Payments | $-752,000 | $-708,000 | $-953,000 | $-1,256,000 |
| Long Term Debt Issuance | $13,445,000 | $0 | $0 | $3,975,000 |
| Net Intangibles Purchase And Sale | $0 | $-215,000 | $0 | $-1,598,000 |
| Purchase Of Intangibles | $0 | $-215,000 | $0 | $-1,598,000 |
| Net PPE Purchase And Sale | $-41,000 | $-16,000 | $0 | $-77,000 |
| Purchase Of PPE | $-41,000 | $-16,000 | $0 | $-77,000 |
| Change In Working Capital | $16,509,000 | $-3,010,000 | $-11,099,000 | $-4,428,000 |
| Change In Other Working Capital | $-171,000 | $723,000 | - | - |
| Change In Other Current Liabilities | $-272,000 | $-451,000 | $-394,000 | $-315,000 |
| Change In Other Current Assets | $1,173,000 | $-336,000 | $-17,000 | $-550,000 |
| Change In Payables And Accrued Expense | $5,402,000 | $-803,000 | $-3,810,000 | $542,000 |
| Change In Accrued Expense | $2,056,000 | $-1,131,000 | $-2,955,000 | $-360,000 |
| Change In Payable | $3,346,000 | $328,000 | $-855,000 | $902,000 |
| Change In Account Payable | $3,346,000 | $328,000 | $-855,000 | $902,000 |
| Change In Prepaid Assets | $10,670,000 | $-1,513,000 | $-5,011,000 | $-1,560,000 |
| Change In Inventory | $-254,000 | $-1,156,000 | $-2,165,000 | $-2,124,000 |
| Change In Receivables | $-39,000 | $526,000 | $298,000 | $-421,000 |
| Changes In Account Receivables | $6,000 | $440,000 | $-88,000 | $-170,000 |
| Other Non Cash Items | $153,000 | $283,000 | $13,377,000 | $12,581,000 |
| Stock Based Compensation | $831,000 | $1,641,000 | $2,112,000 | $3,318,000 |
| Unrealized Gain Loss On Investment Securities | $6,266,000 | $9,485,000 | $5,125,000 | $21,000 |
| Provisionand Write Offof Assets | $2,000,000 | $0 | - | - |
| Asset Impairment Charge | $800,000 | $0 | $371,000 | $0 |
| Depreciation Amortization Depletion | $2,202,000 | $2,358,000 | $2,388,000 | $2,292,000 |
| Depreciation And Amortization | $2,202,000 | $2,358,000 | $2,388,000 | $2,292,000 |
| Depreciation | $2,202,000 | $2,358,000 | $2,388,000 | $2,292,000 |
| Earnings Losses From Equity Investments | $162,000 | $138,000 | $51,000 | $0 |
| Net Income From Continuing Operations | $-54,408,000 | $-39,034,000 | $-41,870,000 | $-49,075,000 |
| Proceeds From Stock Option Exercised | - | $0 | $1,236,000 | $0 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-24